page

Explore expert perspectives, trends, and innovations <br />
shaping the future of specialty chemicals and your market.

Insights 
from the Industry

Industry Articles


What&nbsp;is&nbsp;PVDF?&nbsp;



PVDF (polyvinylidene fluoride) is a semi-crystalline thermoplastic fluoropolymer — meaning it is both a thermoplastic (melt-processable, recyclable) and a fluoropolymer (fluorine-containing backbone). It combines the processing advantages of thermoplastics with the chemical and thermal resistance characteristic of fluoropolymers, making it uniquely suited to demanding industrial, energy and pharmaceutical applications.



Polyvinylidene fluoride (PVDF) is a semi-crystalline thermoplastic fluoropolymer produced by the polymerization of vinylidene difluoride (VDF). It occupies a distinctive position in the fluoropolymer family.It is more processable than PTFE, denser with better mechanical strength than most commodity plastics, and uniquely capable of exhibiting piezoelectric behavior depending on its crystalline structure. &nbsp;



PVDF has a set of valuable properties :




a relatively high melting point,



high mechanical strength even at elevated temperatures,



chemical and raditation resistance.




This combination explains why PVDF has expanded far beyond its original niche in chemical handling into electronics, energy storage, filtration, biomedical devices, and architectural coatings.



Applications of PVDF — By Industry and Grade



Polyvinylidene Fluoride Properties: At a Glance







Chemical&nbsp;resistance&nbsp;



PVDF expresses inherent resistance to ozone oxidation, nuclear radiation, UV damage, and microbiological and fungal growth — a profile that is fairly distinctive among thermoplastic materials. This resistance stems from the elemental stability of its carbon–fluorine bonds. It withstands most mineral acids, halogens, and aromatic solvents, though hot concentrated sulfuric acid and hot amines represent known limits of resistance.



Thermal&nbsp;stability&nbsp;



PVDF maintains useful properties across a wide temperature range, from −30 °C to 170°C.Its thermal degradation temperature remains in the 400–450 °C range regardless of the crystalline phase or manufacturing method used. MDPI This stability underpins its suitability for high temperature industrial processing environments.



Mechanical&nbsp;performance&nbsp;



PVDF is one of the most rigid and abrasion-resistant of the melt-processable fluoropolymers, with excellent resistance to stress fatigue, abrasion, and cold flow. Compared to fully fluorinated polymers such as PTFE, PVDF offers superior mechanical strength and better dimensional stability under load.



Electrical&nbsp;properties&nbsp;



PVDF exhibits a relatively high dielectric constant and low dielectric loss across a wide frequency range, making it suitable for insulation and capacitive applications.Crucially, in its electroactive crystalline form, it also develops piezoelectric and pyroelectric behavior — the ability to generate an electric charge in response to mechanical stress or temperature change — which distinguishes it from virtually all other melt-processable engineering polymers.



UV and&nbsp;weathering&nbsp;resistance&nbsp;



As a fine powder grade, PVDF is an ingredient in high-end architectural paints for metals. These coatings have extremely good gloss and color retention and are used on many prominent buildings around the world.&nbsp; This weathering durability is a direct consequence of the strength and inertness of its carbon–fluorine backbone.



What&nbsp;crystalline phases&nbsp;does&nbsp;PVDF&nbsp;form, and&nbsp;why&nbsp;does&nbsp;it&nbsp;matter?&nbsp;



One of the most technically significant aspects of PVDF is its crystalline polymorphism. Depending on how the polymer is processed, it can adopt several distinct structural phases, each with different property profiles.



The α-phase is the form that crystallizes naturally from the melt. It is non-polar and therefore does not exhibit piezoelectric properties. It is the dominant phase in most standard industrial processing.



The β-phase is the most electroactively valuable form. In the β-phase, the electronegative fluorine and electropositive hydrogen atoms are located on opposite sides of the polymer's carbon–carbon backbone, creating a net dipole moment that renders the piezoelectric properties to PVDF. This phase does not form spontaneously and must be induced through specific processing treatments such as mechanical stretching, high-pressure crystallization, or electrical poling.



The γ-phase is an intermediate form with weaker electroactive properties than β, typically obtained by solution casting or annealing near the melting point.



The practical implication is clear: the same base polymer can behave very differently depending on processing conditions. FOrs tructural or chemical resistance applications, the α-phase is entirely adequate. For sensor, actuator, or energy harvesting applications, maximizing β-phase content is critical.



What&nbsp;grades of PVDF&nbsp;exist?&nbsp;



PVDF is available in a range of grades tailored to different processing routes and end-use requirements. The two fundamental categories are homopolymers and copolymers.



Homopolymer grades deliver the highest crystallinity, the strongest mechanical properties, and the greatest chemical resistance. They are the standard choice for piping, chemical equipment, and applications requiring maximum purity or electrochemical stability.



Copolymer grades — primarily based on VDF copolymerized with hexafluoropropylene (HFP) or chlorotrifluoroethylene (CTFE) — trade some crystallinity for improved flexibility and lower processing temperatures. Copolymers with CTFE are among the most flexible PVDF products, showing excellent low-temperature performance and low shrinkage, making them ideal for wire, cable and tubing applications requiring enhanced flexibility.



Beyond the homopolymer/copolymer distinction, grades are further differentiated by:




Melt viscosity, which determines suitability for extrusion versus injection molding



Particle size and form (pellets vs. powder vs. dispersion), which is critical for coating applications and battery slurry preparation



Purity level — industrial, semiconductor, and battery grades differ significantly in their contamination thresholds



Molecular weight, which influences mechanical performance and melt flow behavior




For a broader perspective on how resin grade selection affects formulation and processing outcomes across polymer families, see our dedicated guide.





How&nbsp;is&nbsp;PVDF&nbsp;processed?&nbsp;



PVDF can be processed using techniques applicable to standard thermoplastics. Processing temperatures range between 190 and 280 °C. Drying of the resin before processing is usually not necessary, but care must be taken to eliminate dead zones where molten resin can collect and thermally decompose if residence time is excessive.&nbsp;



Extrusion&nbsp;



Extrusion is the dominant route for producing PVDF pipes, tubes, rods, films, and sheet. Controlled screw design, temperature profiling, and the elimination of stagnation points are essential to maintain polymer stability and surface quality. PVDF is available in the form of piping products, sheet, tubing, films, plate, and as an insulator for premium wire. It can be injected, molded, or welded.&nbsp;



Injection&nbsp;molding&nbsp;



Injection molding is used to produce precision components such as fittings, connectors, valve bodies, and housings. Appropriate mold design, temperature control, and shrinkage compensation are necessary to obtain dimensionally accurate parts.



Solution&nbsp;processing&nbsp;and&nbsp;coating&nbsp;



PVDF can be dissolved in polar solvents such as N-methylpyrrolidone (NMP), dimethylformamide (DMF), or dimethyl sulfoxide (DMSO) to form solutions suitable for casting films, preparing battery electrode slurries, or applying functional coatings. Solution-based processing routes include solution casting, spin coating, and film casting.



Compression&nbsp;molding&nbsp;and&nbsp;powder&nbsp;processing&nbsp;



Powder grades of PVDF are used in compression molding, rotational lining, and spray coating. As a fine powder or aqueous dispersion, PVDF is also the basis of high-performance architectural coatings applied to metal cladding panels.



What&nbsp;are the main application areas for&nbsp;PVDF?&nbsp;



Chemical&nbsp;processing&nbsp;equipment&nbsp;



Valves, piping, and other solid and lined components are typical applications of PVDF in chemical processing equipment. It is the only fluoroplastic available in rigid pipe form.&nbsp; It is also used for pump impellers, tank linings, heat exchanger tubes, and fittings in plants handling aggressive acids, solvents, and oxidizing agents.



Electrical&nbsp;and&nbsp;electronics&nbsp;



PVDF is commonly used as insulation on electrical wires because of its combination of flexibility, low weight, low thermal conductivity, high chemical corrosion resistance, and heat resistance. It is also used in high-frequency electronic devices and as a substrate or functional layer in flexible electronics.



Sensors,&nbsp;actuators, and&nbsp;energy&nbsp;harvesting&nbsp;



The β-phase piezoelectric properties of PVDF make it the polymer of choice for flexible sensors and transducers, acoustic emission detectors, pressure sensors, and vibration-based energy harvesting devices. Unlike ceramic piezoelectric materials, PVDF is lightweight, flexible, and biocompatible, making it uniquely suited to wearable and implantable sensor applications.



Lithium-ion batteries&nbsp;



PVDF has been the dominant polymeric binder in the mass production of lithium-ion batteries for decades. It has a good binding capacity while swelling to a limited extent in the electrolyte, facilitating the transfer of lithium ions to the surface of the active material. It is used both as a cathode and anode binder and as a separator coating in gel-polymer battery architectures. Battery-grade PVDF is subject to tight purity and particle size specifications that differentiate it significantly from industrial grades.



Filtration membranes&nbsp;



PVDF is used in biotechnology as a membrane to immobilize proteins and as a binder component for electrochemical applications. More broadly, PVDF membranes are widely used in ultrafiltration and microfiltration for water treatment, pharmaceutical filtration, and semiconductor ultrapure water systems, valued for their chemical durability, controllable porosity, and resistance to fouling treatments.



Architectural&nbsp;coatings&nbsp;



PVDF-based coatings applied as liquid or powder to metal cladding offer outstanding resistance to UV radiation, color fading, chalking, and atmospheric pollutants. This application relies on powder or dispersion grades and typically uses a blend of PVDF with acrylic resins to optimize both film formation and durability. The result is a coating with a service life measurable in decades — a property profile explored in depth in our article on sustainable coating systems.



Biomedical&nbsp;and&nbsp;pharmaceutical&nbsp;



PVDF can be used as a component of implants and sutures, as an engineering plastic in aggressive biological environments, as a component of transducers and sensors in the field of process control, and in the synthesis of separation membranes for biomedical applications. Its physiological inertness and mechanical robustness make it a credible alternative to metallic implant materials in selected structural applications.



How&nbsp;does&nbsp;PVDF compare to&nbsp;other&nbsp;fluoropolymers?&nbsp;



PVDF is often evaluated alongside PTFE, PFA, and ETFE. The key differentiator is processability: unlike PTFE, which cannot be melt-processed conventionally, PVDF is fully compatible with standard extrusion and injection molding equipment. Although the insulating properties and chemical inertness of PVDF are not as good as those of fully fluorinated polymers such as PTFE and FEP, the balance of properties available in PVDF qualifies it for many engineering applications across a temperature range from −73 to 149 °C.&nbsp;



Where PTFE excels in extreme chemical inertness and continuous high-temperature performance, PVDF offers better mechanical strength, easier and less costly processing, wider grade differentiation, and the unique advantage of electroactive behavior — a capability entirely absent in PTFE.



Key&nbsp;technical&nbsp;takeaways&nbsp;for&nbsp;formulators&nbsp;and&nbsp;engineers&nbsp;



PVDF is not a monolithic material. Grade selection, crystalline phase management, and processing route together determine whether the resulting part or coating will perform as a chemical-resistant structural component, a high-purity battery binder, a flexible piezoelectric sensor, or a decades-durable architectural finish. Understanding those levers — and matching them to application requirements — is the starting point for any serious formulation or design work involving this polymer.



FAQ on PVDF



What does PVDF stand for?



PVDF stands for polyvinylidene fluoride (also written polyvinylidene difluoride), a semi-crystalline thermoplastic in the fluoropolymer family. Its repeating unit — (CH₂–CF₂)n — alternates hydrogen and fluorine atoms, which drives its core pvdf properties: chemical durability, thermal stability, and piezoelectricity. Understanding what is pvdf starts with this structural duality, which distinguishes it from fully fluorinated polymers like PTFE.



What is the difference between PVDF homopolymer and PVDF-HFP copolymer?



PVDF homopolymer offers maximum crystallinity, stiffness, and chemical resistance. PVDF-HFP introduces hexafluoropropylene co-monomers that disrupt chain packing, reducing crystallinity and lowering the glass transition temperature. The result is a softer, more flexible material with higher ionic conductivity — a key advantage in gel polymer electrolytes — at the cost of some mechanical strength relative to the homopolymer.



Is PVDF food safe or biocompatible?



PVDF is approved for food and drinking water contact under FDA regulations and the European food contact regulation (EU 10/2011). In biomedical contexts, it is used in surgical sutures, hernia meshes, and implantable sensors. Its piezoelectric β-phase also enables active biomedical devices, though implant-grade applications require full device-level validation beyond material classification alone.



Can PVDF be recycled or is it considered sustainable?



As a thermoplastic, PVDF is theoretically recyclable through melt reprocessing, and closed-loop schemes have been explored for photovoltaic backsheets. In practice, fluoropolymer recycling infrastructure remains limited, and PVDF faces tightening PFAS scrutiny in the EU. Its long service life partially offsets end-of-life challenges, but the material does not qualify as inherently sustainable under current circular economy standards.



What solvents dissolve PVDF?



PVDF dissolves in polar aprotic solvents: N-methyl-2-pyrrolidone (NMP), dimethylformamide (DMF), dimethylacetamide (DMAc), and dimethyl sulfoxide (DMSO). Solubility is temperature-dependent, and solution concentration critically affects membrane morphology in phase inversion casting — central to polyvinylidene fluoride uses in filtration. Aliphatic hydrocarbons, water, and alcohols do not dissolve PVDF, which underpins its use in aqueous chemical environments.




Homopolymers and copolymers for coatings, membranes and batteries.

Looking for PVDF grades?

Coatings, Inks &amp; Construction Industrial specialties Plastics Polyurethane

Polyvinylidene Fluoride (PVDF): Properties, Grades, Applications and Processing

Light stabilizers for plastics, coatings and adhesives, from leading producers.

UV absorbers and HALS

Coatings, Inks &amp; Construction Plastics Rubber

UV Light Stabilizer Additives &amp; HALS: A Practical Guide for Formulators


Ten years ago, plant protein was a protein conversation.



A brand team would brief a product by grams per serving, PDCAAS or DIAAS score, and cost. Pea vs soy vs rice. That was the vocabulary. That was the pitch to the consumer: as much protein as dairy, without the dairy.



That brief is dead. Plant protein products priced and positioned as dairy-equivalent commodities are losing shelf velocity across most major European markets, because consumers who want a scoop of protein are now comparing plant products to each other — not to whey. The question isn't whether you have 25 grams per serving. The question is whether your product tastes like something a real adult wants to drink every morning for a year.



What the 2026 consumer actually rejects



Three signals will get a plant protein product sent back to R&amp;D:



Off-notes



Pea beaniness. Rice grittiness. Soy's papery aftertaste. Plant protein isolates deliver protein and sensory baggage at the same time. The consumer who pays a premium for a differentiated product will not tolerate the baggage.



Solubility and mouthfeel



Chalky suspensions, separation in shakers, poor dispersion in cold water, gritty settling. These are all solvable formulation problems that most brands don't fully solve.



Single-origin dependency



A brand built exclusively on one protein source — particularly pea — is increasingly exposed to supply, pricing, and allergen concerns. Multi-origin blends are the new baseline, both for nutritional profile and for supply resilience.



The brands winning the category in 2026 are treating plant protein as a sensory and supply-chain problem first, a protein problem second.



The portfolio question



Safic-Alcan gives formulators access to one of the broadest multi-origin plant-protein portfolios in Europe:




Pea — isolates, concentrates, textured



Soy — isolates, concentrates, textured, hydrolysates



Wheat — gluten, hydrolysed wheat proteins, textured



Rice — concentrates, isolates, organic grades



Faba bean — isolates, concentrates, textured



Chickpea — concentrates, flours



Lentil — concentrates, flours



Oat — concentrates, isolates



Potato — isolates



Sunflower — isolates, concentrates



Pumpkin seed — concentrates



Hemp — concentrates, hearts



Almond, cashew, peanut — protein powders



Mung bean — isolates



Algae and microalgae — spirulina and others




That breadth exists because sensory and supply-chain optimisation requires it. A dairy-alternative yogurt, a sports nutrition shake, a meat analogue, and a high-protein RTD all need different blends — not different marketing. Our Life Sciences team supports the formulation work.





The body-composition brief



Plant protein is no longer just a meat-alternative or dairy-alternative play. It's a weight management and longevity ingredient, which is where the category is quietly migrating.



In the GLP-1 era, consumers and clinicians are increasingly concerned about lean mass preservation during rapid weight loss. A 2024 meta-analysis of 22 GLP-1 receptor agonist trials found that approximately 25% of total weight lost on these therapies came from lean mass, with semaglutide 2.4 mg weekly among the least effective at preserving it. Protein intake sufficient to support muscle protein synthesis is one of the few non-pharmaceutical levers available — which is why adequate high-quality protein has become a standard clinical recommendation for GLP-1 patients.



High-quality plant protein — particularly from blends that cover the full amino acid profile — is a practical answer. Satiety-oriented formulations, muscle-recovery positioning, and "adequate protein in mid-life" longevity formulations are all growing faster than base sports nutrition.



Pair plant protein with AvailOm® High EPA for joint recovery and inflammation claims, or with Morosil® for body composition-focused weight management products, and the stack tells a story the dairy protein category cannot match on sustainability and consumer trust.



Energy, vitality, and the functional stack



Plant protein is the anchor of the energy and vitality category, but it's rarely the whole story. The 2026 sports nutrition brief typically includes creatine, BCAAs or EAAs, peptides, caffeine or caffeine alternatives, electrolytes, and increasingly functional botanicals and mushroom extracts for energy and cognitive support.



Safic-Alcan's Life Sciences portfolio covers the full stack. The microbiota layer — gut-performance and gut-brain axes — is the frontier most sports nutrition brands are under-formulating.



Meet us in Barcelona



The full multi-origin plant-protein portfolio, the complementary actives (creatine, peptides, AvailOm®, Morosil®), and technical and regulatory support from our Life Sciences team — all on our stand at Vitafoods Europe 2026.



Bring your brief. Come taste the difference.



→ 5–7 May 2026 · Fira Barcelona Gran Via · Booth 3B143






Register today for Vitafood and come visit ut at our booth

Vitafood is just around the corner!

Plant protein isn't about protein anymore


Every consumer knows about the gut microbiome now. Brand teams should treat that as bad news.



When a category concept is universally understood, it stops being a differentiator. "Probiotics" printed on a pack used to signal innovation. In 2026 it signals baseline — the equivalent of a shampoo bottle saying "contains water." The CFU count arms race is over; nobody on the consumer side reads the number anymore, and most of the clinically meaningful differences between products never lived in the CFU count to begin with.



The brands winning microbiota-positioned launches in 2026 are doing three things differently.



1. They've moved from probiotics to the full stack



The modern microbiota brief is not "add a probiotic." It's an architecture:




Prebiotics — substrates that selectively feed beneficial strains (inulin, FOS, GOS, resistant dextrins, specific plant polyphenols). The ISAPP consensus defines a prebiotic as "a substrate that is selectively utilized by host microorganisms conferring a health benefit".



Probiotics — live strains with documented survival through gastric transit and clinical endpoints at realistic doses.



Postbiotics — formally defined by ISAPP in 2021 as a "preparation of inanimate microorganisms and/or their components that confers a health benefit on the host". The category unlocks matrix compatibility that live-strain products cannot match.



Yeast and fungi — Saccharomyces boulardii and selected fungal components with distinct clinical profiles.



Synbiotic and postbiotic combination stacks — built for a specific claim, not a generic "gut health" label.




Safic-Alcan's Life Sciences portfolio covers all five. For formulators moving beyond single-strain probiotic products, the combination possibilities are where the differentiation lives.



2. They've moved from "gut health" to specific axes



"Gut health" is a claim category the consumer has learned to discount. The signal is in the axes — gut plus something else:




Gut-skin axis — microbiota strains and metabolites linked to skin barrier function, inflammatory markers, and visible skin outcomes. The scientific anchor for beauty-from-within claims beyond collagen alone.



Gut-brain axis — strains with clinical data on mood, stress, cognitive markers, and sleep. A mainstream mental-wellness claim route for 2026.



Gut-immune axis — the original microbiota claim, still the largest category, but now requiring specificity on strain and endpoint.



Gut-metabolic axis — strains and postbiotics linked to glucose regulation, lipid metabolism, and body composition. The natural complement to Morosil® in weight management formulations.




Each axis has different ingredient logic, different clinical literature, and different regulatory considerations. "Our probiotic supports gut health" is a 2016 claim. The 2026 version names the axis.



3. They've solved survival and format before worrying about CFU



The clinically meaningful variables are:




Strain specificity (down to the strain designation, not just genus + species)



Delivered dose at the point of action, not the point of manufacture



Gastric and bile survival under realistic formulation and storage conditions



Shelf stability across the product's commercial life



Matrix compatibility — can the strain actually live in the gummy, stick, shot, or chocolate the brand wants to build?




This is where postbiotics have quietly become the category's release valve. A bioactive metabolite or heat-inactivated cell preparation with clinical data doesn't need to survive — and opens up formats (RTDs, baked goods, non-refrigerated chains) that live strains can't realistically handle.



Format considerations



Live probiotic strains remain gold standard for many claims, but increasingly formulators are building hybrid stacks: live probiotic as the anchor, prebiotic substrate, postbiotic secondary actives, and a clean-label carrier system that supports stability.



Pair the microbiota stack with AvailOm® omega-3 for combination longevity and cognitive formulations, or with plant proteins for sports and recovery formats, and the architectural possibilities expand quickly.



Meet us in Barcelona



Safic-Alcan's microbiota portfolio covers probiotics, prebiotics, postbiotics, yeasts and fungi across all four major axes, with technical and regulatory support from our Life Sciences team.



→ 5–7 May 2026 · Fira Barcelona Gran Via · Booth 3B143




Beyond CFU counts: the 2026 microbiota stack


GLP-1 agonists did something no supplement brand planned for: they made weight management a medical conversation, not a lifestyle one.



Ozempic and its cousins didn't just change the patient journey. They changed the consumer brief. Weight management brands are now working in two parallel markets: consumers on a GLP-1 who need complementary support, and consumers deliberately not on one who want ingredients that actually earn the category name.



The common denominator in both markets is the same problem, repackaged: lean mass preservation, visceral fat reduction, metabolic health. A 2024 meta-analysis of 22 GLP-1RA trials found that lean mass loss accounted for approximately 25% of total weight lost on these drugs, with semaglutide 2.4 mg weekly among the least effective at preserving lean mass. Individual trials have reported the lean-mass fraction of total weight loss as high as 40–45%. The scale isn't the point anymore. Body composition is.



That's the ingredient brief for 2026.



Why most weight management ingredients aren't built for it



The category's historical toolkit — glucomannan, green tea extract, Garcinia, chromium — does not answer the body-composition question in a clinically defensible way. Most of this literature is thin, old, or measures the wrong outcome. A 12-week study showing "reduced body weight" against placebo is not the same as a study showing reduced visceral fat over six months with liver safety monitored.



Brand owners formulating for 2026 need ingredients with:




Randomised, placebo-controlled clinical data



Duration long enough to matter (3–6 months)



Body composition endpoints, not just scale weight



Fat mass and fat distribution data, not just BMI



Safety markers, especially liver




Very few weight management ingredients clear all five. Morosil® is one of them.



What the Morosil® data actually says



Morosil® is a standardised extract from a specific cultivar of Sicilian Moro red oranges (Citrus sinensis L. Osbeck), produced by Bionap in the volcanic soils around Mt. Etna. The active phytocomplex is a defined pool of anthocyanins (primarily cyanidin 3-O-glucoside), hydroxycinnamic acids, flavanones and ascorbic acid — standardised batch-to-batch.



The dose is consistent across the published clinical work: 400 mg/day. Two randomised placebo-controlled trials underpin the evidence base.



Cardile et al. 2015 — 12 weeks, Natural Product Research



The first human trial, published in Natural Product Research, supplemented 60 overweight adults with 400 mg/day of Morosil® or placebo for 12 weeks. The active group showed significant reduction in BMI after just 4 weeks, with body weight, BMI, waist circumference and hip circumference all significantly different from placebo by the end of the study (p &lt; 0.05).



Briskey et al. 2022 — 6 months, Nutrients



The 2022 study extended the evidence base to 6 months with an RCT in Nutrients. Overweight but otherwise healthy adults aged 20–65 received 400 mg/day of Morosil® or placebo alongside a calorie-controlled diet and exercise. Results at 6 months, Morosil® vs placebo:




Body mass reduction: 4.2% vs 2.2% (p = 0.015) — roughly 1.9-times greater loss.



BMI: significantly greater reduction (p = 0.019).



Waist circumference: −3.9 cm vs −1.7 cm (p = 0.017).



Hip circumference: −3.4 cm vs −2.0 cm (p = 0.049).



Fat mass: significant reduction (p = 0.012).



Visceral and subcutaneous fat distribution: significantly improved (p = 0.018 and p = 0.006 respectively).



Liver safety: all markers within normal range at 3 and 6 months in both groups.




The mechanism proposed by the authors is regulation of lipid metabolism through fatty acid biosynthesis and oxidation pathways, mediated by the anthocyanin and biophenol pool — not stimulant action, not appetite suppression, not fibre bulking.



A 2025 systematic review of Moro orange extract trials assigned Briskey 2022 a low risk of bias across all GRADE domains, while noting the evidence overall as low to very low certainty given the small number of trials — important context for any brand owner evaluating the literature.



NutraIngredients-USA named Morosil® Weight Management Ingredient of the Year.



Why this maps to the GLP-1-era brief



A weight management ingredient that produces fat-specific body composition improvements — rather than generic scale-weight reduction — is exactly the complementary story a brand owner building GLP-1-adjacent products wants to tell. The Briskey 2022 data demonstrates significant reductions in fat mass, visceral fat and subcutaneous fat alongside waist and hip circumference. For consumers concerned about body composition while on or off a GLP-1, that's the clinical anchor the category has been missing.



Morosil® lands cleanly in both positions.



Formulation notes



Morosil® is a standardised powder extract, suitable for:




Capsules and tablets (most clinical data)



Sticks and sachets



Functional beverages and shots



Gummies




For combination formulations targeting metabolic longevity, pair with AvailOm® High EPA for cardiovascular and inflammation endpoints, or with targeted probiotics for the gut-metabolic axis. High-quality plant protein in the same stack addresses the lean-mass preservation concern that sits alongside fat reduction.



Meet us in Barcelona



Safic-Alcan distributes Morosil® across Europe. The Bionap clinical portfolio, formulation starter formulas, and complementary weight-management ingredients (plant proteins for satiety, peptides for muscle preservation) will be on our stand at Vitafoods Europe 2026.



Vitafoods added Weight Management as a new Innovation Award category this year. It's not a coincidence.



→ 5–7 May 2026 · Fira Barcelona Gran Via · Booth 3B143




Register today for Vitafood and come visit ut at our booth


Morosil® and the GLP-1 era: why body composition is the new weight management brief


Omega-3 is a solved science and an unsolved product.



The science part is comfortable: EPA and DHA, essential for cardiovascular, cognitive, joint and eye function, backed by decades of clinical literature, recognised by every major regulatory body. Consumers know they need it. Brand owners know they should offer it.



The product part is where the category has been stuck for twenty years.



The formats formulators have been forced to live with



Soft gels



Soft gels work, but they're large, the consumer experience is poor (burps, fishy aftertaste, digestion complaints), and they exclude entire formats — no sticks, no gummies, no combination tablets, no functional beverages. For brands building a daily-ritual product for 2026 consumers, the soft gel is a compromise nobody wants to make.



Conventional omega-3 powders



Conventional omega-3 powders are worse. Most are encapsulated oils or oils absorbed onto carbohydrate carriers. The effective EPA+DHA load is low — often below 30% — and the powders are rarely directly compressible into tablets. You end up with bulky formats, compressibility problems at scale, or oxidation issues on shelf.



Ethyl ester



Ethyl ester — the standard concentrate form — requires emulsification via bile salts and hydrolysis by pancreatic lipases before the body can absorb it. Clinically real; commercially fine. But for a longevity-positioned brand trying to tell a bioavailability story, "requires digestion to work" isn't the headline.



The result: for most of the last decade, omega-3 has been the supplement every brand includes and nobody features.



What AvailOm® actually changed



Evonik's AvailOm® is an omega-3 lysine complex: EPA and DHA as free fatty acids, chemically bound to the essential amino acid L-lysine, producing a solid powder with properties the category hadn't seen before.



The primary bioavailability claim is supported by a first-in-human clinical pharmacokinetic study conducted at Wageningen University (The Netherlands) and published in Prostaglandins, Leukotrienes and Essential Fatty Acids in 2020. Evonik confirms the key specifications in its published product documentation[2]:




50% EPA+DHA as free fatty acids by weight — the highest-load omega-3 powder in its class.



~5× higher bioavailability vs a commercial oil-based ethyl-ester formulation (median AUC ratio 5.04 over 0–12h in fasted healthy adults, n=8)[1].



Directly compressible into tablets — smaller, easier-to-swallow formats with combination ingredients.



Multi-year oxidation resistance — shelf stability that opens up global distribution and combination products[2].



No fishy aftertaste or burps — the consumer experience complaint that drives the category's churn.




It's worth noting the Wageningen study's honest scope: it was an acute pharmacokinetic comparison in a fasted state. Independent reviewers have pointed out that the five-times advantage applies most cleanly to the fasted use case and to individuals with compromised fat digestion (low-fat diet, reduced bile availability, gut inflammation)[3]. That still covers a meaningful share of the longevity-consumer profile — and the free fatty acid form plus the oxidation-resistance and direct-compressibility properties deliver the formulation advantages independent of the bioavailability debate.



For formulators, this removes the trade-off between load, stability, and format. You can build a combination tablet with omega-3, botanicals, vitamins, minerals, probiotics — and stand behind the EPA+DHA content on the label.



Three grades, three briefs



AvailOm® comes as a platform, not a single product:




AvailOm® 50 High EPA — minimum 30% EPA + 15% DHA. EPA is associated with cardiovascular, joint and inflammation endpoints. The healthy-ageing grade — the one to specify for longevity-positioned adult brands.



AvailOm® 50 High DHA — fish-oil-derived, higher DHA concentration. DHA is associated with cognitive function, eye health, and infant development. Pregnancy, maternity, and cognitive-ageing positioning.



AvailOm® 50 High DHA Algae — algae-oil-based, minimum 48% DHA as free fatty acids. Vegan and vegetarian. The grade that makes nutricosmetic and cognitive formulations work for the beauty-from-within category.




All grades are sustainably sourced and cleared for marketing in Europe, the US, and most major markets.



Longevity is mid-life now



The longevity conversation in 2026 is not about ageing. It's about the 40-year-old reading Peter Attia, tracking their ApoB, and formulating their own protocol. These consumers read labels. They compare EPA:DHA ratios. They know what "free fatty acid form" means. They notice when a product avoids the soft gel for good reasons.



AvailOm® is the ingredient that lets a brand answer that consumer seriously.



Pair it with clinically-proven weight management ingredients like Morosil® for a metabolic-longevity positioning, or with the right microbiota stack for a systems-level healthspan brief.



Meet us in Barcelona



Safic-Alcan distributes AvailOm® across Europe. The full three-grade range, plus the complementary portfolio for longevity formulations (carotenoids, DHA, antioxidants, minerals), will be on our stand at Vitafoods Europe 2026.



→ 5–7 May 2026 · Fira Barcelona Gran Via · Booth 3B143




Learn more about our presence









How AvailOm® is solving the omega-3 problem brands have been working around


For years, "vegan collagen" was a workaround.



Brand teams knew it. Formulators definitely knew it. The vitamin C + amino acid + silica stack sold as "vegan collagen support" wasn't collagen — it was the cofactors for the collagen your body already makes. Useful biology. Dishonest label.



The consumer got the joke eventually. Returns went up. Trust went down. And the beauty-from-within category — one of the fastest-growing in nutraceuticals — kept carrying a credibility problem nobody wanted to name.



That's changing, on two fronts at once: the arrival of genuine precision-fermented vegan collagen peptides, and a much richer segmentation inside the marine category itself.



What precision fermentation actually unlocks



Collagen is absent from plants. Its building blocks are not. Modern precision fermentation takes that second fact seriously: recombinant collagen peptides, bioidentical to human Type I, produced by engineered microbes, purified to pharmaceutical-grade standards.



The result is a real ingredient, not a proxy. Neutral sensory profile. Compatible with capsules, gummies, powders, beverages, sticks. Vegan and vegetarian certifiable. No bovine spongiform concerns, no fish allergen, no marine sourcing volatility.



For brand owners, this changes the brief completely:




The label says "collagen" and means it.



The sensory profile doesn't fight the formulation.



The sustainability narrative is defensible without handwaving.



The consumer doesn't need to be educated on why the old "boosters" weren't the real thing.




That last point is where most of the category velocity will come from in 2026–27. Safic-Alcan is actively onboarding precision-fermented suppliers as this tier matures — speak to our Life Sciences team for the current state of play.



The marine range doing most of the real work today



While the vegan recombinant tier develops, the marine category has quietly become far more sophisticated than the "fish collagen peptide" of five years ago. Type I collagen — the dominant structural collagen of human skin, accounting for the majority of the dermal extracellular matrix — is also the dominant form of marine collagen, which explains the category's durability. The Safic-Alcan catalogue carries several distinct grades, each with a different brief:




AQUAPRO® Fish Collagen Type I Tripeptide (JXN Collagen Life Sciences) — a hydrolysed marine peptide derived from fish scales, optimised for nutraceutical applications where low molecular weight and rapid bioavailability matter. The tripeptide form is the shortest structurally meaningful collagen fragment, which has implications for absorption kinetics.



Fish Collagen Peptide Type II (JXN Collagen Life Sciences) — designed for nutraceuticals and dietary supplements with Type II–specific endpoints: joint, skin, bone health, and anti-inflammatory positioning. Type II is the matrix protein of cartilage and is the correct specification for joint-led product briefs.



Collagen HM (Copalis) — a marine polypeptide engineered for sports nutrition and skin rejuvenation. The dual positioning matters: brands building performance + recovery + beauty crossover products (an increasingly common brief) don't need two different collagens.



Collactive® (Copalis) — marine collagen combined with elastin oligopeptides, positioned as an antioxidant for nutraceutical applications. Elastin is the structural partner to collagen in skin, and the combination story is defensible in a way that collagen-only formulations are not.



Fish Collagen Peptide — the standard hydrolysed marine grade for nutraceuticals and dietary supplements, with the broadest clinical literature base for skin, joint, and bone endpoints.




Marine collagen peptides are widely reported to offer approximately 1.5-times higher absorption than land-animal sources, attributed to their smaller average peptide molecular weight. The sustainability narrative — fish by-products, circular-economy sourcing — is equally defensible. Flavour-masking is recommended in neutral matrices; the Life Sciences team supports that work.



Plant-based alternatives for the cosmetic-adjacent side of the category



Some "beauty from within" briefs are really topical-adjacent — ingredients specified for a combined ingestible and cosmetic line, or for brands that want a single botanical signature across the range. For that positioning:




Collagen PhytPowder 300 (Greenphyt) — an antioxidant, radiance promoter, restoring and firming agent designed for masks and body wraps, suitable for water-based formulations.



Carrot Collagen (Hyundai Bioland) — a moisturising agent for skin care applications, positioned as a plant-based alternative to animal collagen.




These are cosmetic-side products rather than ingestible nutraceuticals, but they're worth knowing about if your brief spans both sides of the beauty-from-within architecture.



The complement most brands under-formulate



Beauty from within isn't just collagen. Skin ageing is systemic: oxidative stress, inflammation, omega-3 status, gut health, cognitive markers. The brands winning 2026 are building stacks, not single-ingredient capsules.



DHA — the omega-3 fatty acid associated with cognitive and eye health — also matters for skin barrier function. AvailOm® High DHA Algae is the vegan-compatible format most formulators haven't built in yet: 48% DHA as free fatty acids, algae-based, directly compressible, no fishy profile.



And the gut-skin axis is no longer fringe. The 2026 microbiota stack is becoming central to any nutricosmetic brief that wants to hold up under consumer scrutiny.



Meet us in Barcelona



The full collagen spectrum — marine Type I and Type II, Collactive® marine + elastin, plant-based alternatives — plus the complementary stack (omega-3, probiotics, carotenoids, vitamins) will be on our stand at Vitafoods Europe 2026.



→ 5–7 May 2026 · Fira Barcelona Gran Via · Stand 3B143




Learn more about our presence





Why the collagen category is finally growing up


Europe's synthetic rubber landscape has shifted more in the past three years than in the&nbsp;previous&nbsp;decade. Sanctions on Russian feedstocks, a wave of plant closures driven by energy costs, and the arrival of Euro 7&nbsp;tyre&nbsp;abrasion rules have fundamentally changed the supply dynamics for styrene-butadiene rubber (SBR). For compounders, procurement teams, and formulation specialists, the market they navigate today bears little resemblance to the one that existed before 2022. This article examines what has changed, why it matters, and how sourcing strategies need to&nbsp;adapt.&nbsp;



What is SBR, and why does it matter&nbsp;for&nbsp;European industry?&nbsp;



Styrene-butadiene rubber is the world's highest-volume synthetic elastomer.&nbsp;According to S&amp;P Global's Chemical Economics Handbook, SBR is produced by&nbsp;copolymerising&nbsp;butadiene and styrene at&nbsp;roughly a&nbsp;3:1 ratio. Two main process families exist:&nbsp;emulsion SBR (E-SBR), which still dominates installed global capacity, and&nbsp;solution SBR (S-SBR), where&nbsp;virtually all&nbsp;new investment is being directed. S-SBR's narrower molecular weight distribution and&nbsp;functionalisation&nbsp;potential make it the polymer of choice for low-rolling-resistance&nbsp;tyre&nbsp;treads — a performance parameter that is now regulated under EU&nbsp;tyre&nbsp;labelling rules.&nbsp;



The end-use split is lopsided:&nbsp;tyres accounted for approximately 68.72% of SBR demand in 2025, with the&nbsp;remainder&nbsp;split across footwear outsoles, adhesives, conveyor belts, technical&nbsp;moulded&nbsp;goods, and polymer-modified bitumen for road construction. Europe's consumption is driven overwhelmingly by its&nbsp;tyre&nbsp;manufacturing industry, concentrated in Germany, France, and Italy — and that demand is shifting structurally toward solution grades.&nbsp;



For the fundamentals of rubber reinforcement that sit alongside SBR in every&nbsp;tyre&nbsp;formulation,&nbsp;Safic-Alcan's article&nbsp;Decoding Carbon Black and Its Crucial Role in the Rubber Industry&nbsp;covers the companion&nbsp;filler&nbsp;chemistry in depth.&nbsp;



The E-SBR / S-SBR distinction: why it matters for sourcing&nbsp;



Understanding the difference between emulsion and solution SBR is a prerequisite for any serious sourcing conversation in Europe today.&nbsp;



E-SBR&nbsp;is produced by&nbsp;polymerising&nbsp;styrene and butadiene monomers in a water-based emulsion at low or high&nbsp;temperature. It is a cost-effective, broadly compatible workhorse grade — the standard choice for passenger and truck&nbsp;tyre&nbsp;carcass compounds, conveyor belts, footwear soles, and general mechanical goods.&nbsp;E-SBR still represented approximately 70.42% of global SBR market volume in 2025, and the large majority of European SBR production capacity is emulsion-based. It is also the grade most affected by the supply-side disruptions discussed below.&nbsp;



S-SBR&nbsp;is produced via anionic solution&nbsp;polymerisation, typically using an organolithium initiator in a hydrocarbon solvent. The process allows precise control over molecular architecture — vinyl content, styrene distribution, molecular weight — and enables end-group&nbsp;functionalisation&nbsp;that improves filler interaction with silica.&nbsp;From 2019 to 2024, demand for E-SBR declined while S-SBR demand surged, highlighting a significant market shift toward grades that meet the stringent specifications of high-performance tyres. S-SBR commands a significant price premium over commodity E-SBR, and capacity additions have been concentrated in this segment.&nbsp;



The practical sourcing implication: the European market faces a two-speed reality. E-SBR is tight due to capacity reductions (see below). S-SBR demand is growing fast but a meaningful&nbsp;portion&nbsp;of high-performance supply still originates from Asia, particularly South Korea and Singapore, with the attendant&nbsp;logistics, lead-time, and emerging carbon-border adjustment risks.&nbsp;



Structural capacity contraction in European SBR production&nbsp;





Europe's synthetic rubber production base has contracted materially since 2021, for reasons that are structural rather than cyclical.



The energy cost problem&nbsp;



Europe's chemical industry entered a deep competitiveness crisis after 2021, when energy costs — natural gas in particular — rose dramatically following Russia's invasion of Ukraine. Synthetic rubber production is energy-intensive: utilities&nbsp;represent&nbsp;a major share of operating costs, particularly for emulsion&nbsp;polymerisation, which requires continuous temperature control and steam.&nbsp;Cefic, the European chemical industry council, estimated that 5% of Europe's total chemical production capacity was shut down in 2023 alone because it was uncompetitive, with more closures following in 2024 and 2025.&nbsp;



Within the polymer and elastomer sector,&nbsp;announced capacity closures in Europe accelerated from 2.9 million tonnes in 2022 to 17.2 million tonnes by 2025&nbsp;across the broader chemicals landscape, with polymers accounting for a significant share.&nbsp;In half of the cases, companies cited energy cost competitiveness as the primary rationale for closing. For E-SBR specifically, European production economics became structurally uncompetitive compared to Asian producers&nbsp;operating&nbsp;with cheaper feedstocks and energy, and against Chinese producers adding capacity at scale.&nbsp;



The consequences for European SBR supply are concrete: a French SBR production site with a capacity of approximately 140,000&nbsp;tonnes/year was announced for permanent closure by 2027, citing sustained losses and adverse European market conditions — leaving France without domestic SBR production for the first time in decades. Capacity reductions have also occurred in Central Europe, where one major E-SBR production line was permanently idled due to unsustainable utility costs. European synthetic rubber production, which previously&nbsp;benefited&nbsp;from geographic proximity to the continent's large&nbsp;tyre&nbsp;manufacturing base, is now a smaller, more concentrated, and more premium-oriented industry than it was five years ago.&nbsp;



The Russia sanctions shock&nbsp;



The second structural disruption is the permanent removal of Russian SBR from the European supply pool. Russia was historically one of the largest exporters of emulsion SBR to European&nbsp;tyre&nbsp;plants, supplying a meaningful share of the continent's commodity E-SBR requirements at competitive prices.&nbsp;



In February 2023,&nbsp;the EU's tenth sanctions package introduced import quotas on Russian synthetic rubber and carbon black, with a full import prohibition taking effect on 1 July 2024. The original quotas were set at 562,973&nbsp;tonnes&nbsp;for synthetic rubber and 752,475&nbsp;tonnes&nbsp;for carbon black — calibrated to pre-war import levels, which gives a clear sense of how significant this supply source had been. Beyond the direct prohibition,&nbsp;the European Commission established a monthly monitoring mechanism on inflows, and successive sanctions packages have continued to close circumvention routes, with the 19th package in force from October 2025 adding further rubber articles to the restricted list.&nbsp;



For procurement teams, the practical implication is harder&nbsp;due&nbsp;diligence on origin declarations — particularly for material routed through third countries where repackaging and re-certification risk is real. The import prohibition covers CN code 4002 synthetic rubber; compliance teams should ensure traceability documentation reflects actual origin, not just the country of last shipment.&nbsp;



The regulatory overlay reshaping SBR demand&nbsp;



Three regulatory forces are now actively influencing both the volume and grade mix of SBR purchased in Europe.&nbsp;



Euro 7&nbsp;tyre&nbsp;abrasion limits&nbsp;



Adopted in 2024, Euro 7 is the first EU regulation to set particle emission limits for&nbsp;tyre&nbsp;wear — a measure that directly affects the chemistry of&nbsp;tyre&nbsp;tread compounds and, by extension, the specification of SBR.&nbsp;Compliance becomes mandatory for all new M1/N1 vehicle type approvals from 29 November 2026, and for all new M1/N1 vehicles placed on the EU market from 29 November 2027. For&nbsp;tyres&nbsp;specifically,&nbsp;the type-approval requirement for C1 passenger car tyres applies from 1 July 2028, with non-compliant tyres banned from the market from 1 July 2030.&nbsp;



Specific abrasion limits are being&nbsp;finalised&nbsp;at UNECE level, with&nbsp;the Euro 7 Regulation leaving it to UN WP.29 to develop limits by June 2026 for passenger car tyres, March 2028 for light commercial vehicles, and March 2030 for heavier vehicles. If UNECE misses those deadlines, the European Commission is empowered to set EU-level limits unilaterally.&nbsp;



For SBR sourcing, this is a clear and durable demand signal: abrasion performance is now a regulatory compliance parameter, not just a marketing one.&nbsp;Functionalised&nbsp;solution SBR grades — engineered to&nbsp;maximise&nbsp;silica coupling efficiency and&nbsp;optimise&nbsp;the rolling resistance / wet grip / wear resistance triangle — are the route to compliant&nbsp;tyre&nbsp;tread compounds.&nbsp;Tyre&nbsp;manufacturers and their compound suppliers are qualifying these grades now, ahead of mandatory deadlines. Buyers who rely&nbsp;predominantly on&nbsp;commodity E-SBR for&nbsp;tyre&nbsp;applications should be modelling the grade migration their compounds will require over the coming years.&nbsp;



The EU&nbsp;tyre&nbsp;labelling regulation&nbsp;



The EU&nbsp;tyre&nbsp;labelling regulation, which grades&nbsp;tyres&nbsp;on rolling resistance, wet grip, and exterior noise, has been in force since 2012 and was updated in 2021. It directly&nbsp;incentivises&nbsp;the use of&nbsp;functionalised&nbsp;S-SBR by creating consumer and OEM demand for the highest-grade labels — an ongoing structural pull on the SBR grade mix, independent of Euro 7.&nbsp;



CBAM and carbon arbitrage&nbsp;



The EU's Carbon Border Adjustment Mechanism (CBAM) does not yet cover synthetic rubber directly, but its shadow is already influencing sourcing decisions.&nbsp;Buyers looking at Korean or Chinese S-SBR imports as a hedge against European capacity constraints must factor CBAM extension scenarios into their total cost of ownership. As the mechanism extends to more sectors — and as EU carbon pricing applies to domestic production — the landed cost differential between European and Asian SBR will narrow. The direction of travel is clear even without a formal extension: buyers pricing Asian S-SBR against European supply on today's landed cost alone are likely to be modelling a differential that will not hold for the life of a multi-year contract.



Sustainability and the bio-based transition&nbsp;



Sustainability is now an active dimension of SBR procurement, not just a communications exercise. Three trends are reshaping the market:&nbsp;



Bio-based butadiene: The key feedstock for SBR — butadiene — is conventionally derived from petroleum-based steam cracking. Several European producers have announced or are developing processes to produce butadiene from bio-derived ethanol, aiming to offer mass-balance or attributional bio-based SBR to&nbsp;tyre&nbsp;customers. These&nbsp;programmes&nbsp;are primarily driven by&nbsp;tyre&nbsp;manufacturers' Scope 3 targets and by the expectations of automotive OEMs, who are increasingly requiring verified Product Carbon Footprint data for rubber raw materials.&nbsp;



Certified sustainable SBR: ISCC PLUS mass-balance certification is becoming a standard specification for premium&nbsp;tyre&nbsp;compound development. Buyers whose OEM customers have committed to science-based carbon reduction targets by 2030 should treat ISCC PLUS documentation as a buying criterion, not an optional extra. Production sites holding this certification can supply bio-attributed or circular-attributed SBR grades with accompanying carbon footprint data.&nbsp;



Rubber recycling and circular feedstocks: The&nbsp;tyre&nbsp;life cycle creates a closed loop opportunity for recovered carbon black and&nbsp;devulcanised&nbsp;rubber to re-enter compound formulations. 



For a broader view of how sustainability-advantaged raw materials perform against fossil-based references in full rubber compounds,&nbsp;Safic-Alcan's comparative study&nbsp;Driving Sustainability-Advantaged Solutions in Rubber Compounding&nbsp;sets out the formulation framework in detail.&nbsp;



What this means for European buyers: practical sourcing considerations&nbsp;



Pulling the threads together, sourcing SBR in Europe in 2026 involves a set of structural decisions that simply did not exist three years ago.&nbsp;



Domestic supply is tighter and more concentrated.&nbsp;With Russian imports banned, meaningful E-SBR capacity permanently closed in France and reduced in Central Europe, the European production base is smaller, more geographically concentrated in Central and Eastern Europe, and more focused on higher-margin solution grades than it was. Dual-sourcing strategies that previously relied on a Russian or Western European backup line now need to reach into Asia or accept tighter allocation from the remaining European plants. This increases&nbsp;logistics&nbsp;risk, lead times, and compliance overhead.&nbsp;



The grade mix is shifting irreversibly toward S-SBR.&nbsp;Euro 7,&nbsp;tyre&nbsp;labelling, and EV-driven performance specifications are all pulling demand toward&nbsp;functionalised&nbsp;solution grades.&nbsp;S-SBR recorded the highest CAGR at roughly 4.27% through 2031, even as emulsion SBR still represented over 70% of 2025 volumes. For non-tyre&nbsp;applications — footwear, mechanical goods, conveyor belts — E-SBR&nbsp;remains&nbsp;the&nbsp;appropriate workhorse, but tightness in European E-SBR availability is making compound reformulation a more active conversation than it used to be.&nbsp;



Feedstock volatility is structural.&nbsp;Styrene and butadiene monomer costs are directly linked to crude oil and naphtha prices, and European producers do not&nbsp;benefit&nbsp;from the backward-integrated margins that Middle Eastern or Chinese competitors enjoy.&nbsp;Feedstock costs typically represent up to 70% of total SBR manufacturing expenses, leaving European producers structurally exposed to commodity price cycles.&nbsp;Price&nbsp;pass-through clauses and monomer-index-linked contracts are increasingly the norm for buyers seeking margin predictability.&nbsp;



Certification is becoming a specification.&nbsp;ISCC PLUS mass-balance documentation and Product Carbon Footprint data per grade are moving from optional differentiators to standard buying criteria, particularly for automotive OEM platforms with hard 2030 Scope 3 targets. Procurement teams that have not yet built SBR sustainability documentation into their supplier qualification process are behind the curve.&nbsp;



Compounding strategy is a competitive variable.&nbsp;With fewer polymer options on the table at competitive European prices,&nbsp;maximising&nbsp;the performance of each&nbsp;tonne&nbsp;of SBR — through&nbsp;optimised&nbsp;silica/silane systems, bio-based or recovered carbon black,&nbsp;appropriate filler&nbsp;loadings, and incorporation of circular content — is increasingly where margin is made or lost. A distributor with regional compounding laboratory capability and multi-supplier access is, in this environment, a genuinely different proposition than a transactional supply channel.&nbsp;



The bottom line&nbsp;



European SBR sourcing in 2026 is tighter, more regulated, and more complex than the market most buyers learned to navigate a decade ago. Domestic production has contracted permanently: Russian imports have gone and will not return on any realistic planning horizon; energy-cost-driven closures have removed meaningful E-SBR capacity from Western Europe; and the remaining European production base is increasingly oriented toward premium S-SBR for high-performance&nbsp;tyre&nbsp;applications. Asian imports fill gaps at the premium&nbsp;end, but&nbsp;carry CBAM risk and longer lead times. The regulatory clock on Euro 7&nbsp;tyre&nbsp;abrasion limits is ticking, and the grade migration it requires is not a future problem — qualification timelines mean it is a present one.&nbsp;



The compounders who will come through this period best are those treating SBR sourcing, compound specification, and regulatory planning as a single integrated conversation rather than three separate workstreams.&nbsp;


Browse our rubber portfolio, including functionalised solution grades and ISCC PLUS certified options.

Qualifying S-SBR grades ahead of Euro 7?

SBR and Synthetic Rubber Sourcing in Europe 


Out of the roughly 2.4 million tonnes of citric acid produced globally each year, the pharmaceutical industry consumes around 12% — a small share by volume, but one that underpins a disproportionately wide range of drug products. From effervescent analgesics and oral antibiotic syrups to lyophilised biologics and blood collection anticoagulant solutions, citric acid (C₆H₈O₇) is one of the most versatile excipients in modern pharmaceutical formulation.



Its three carboxylic groups and one hydroxyl group give it a combination of properties — acidity, buffering capacity, and metal-ion chelation — that no single-function excipient can match. This article outlines how those properties translate into real pharmaceutical applications, and what formulators need to watch for when designing with citric acid. 









Why Citric Acid Is a Multifunctional Excipient



In pharmaceutical formulation, citric acid is rarely asked to do just one job. As reviewed in Citric Acid: A Multifunctional Pharmaceutical Excipient, its utility comes from a single molecule delivering multiple effects in the same formulation:




pH control pH through its three pKa values of 3.13, 4.76 and 6.40, which allow citric acid and citrate buffer systems to hold pH across most of the range used in oral, topical and parenteral formulations.



Metal-ion chelation, which protects oxidation-sensitive active pharmaceutical ingredients (APIs) from trace metal-catalysed degradation.



Effervescence when combined with carbonate or bicarbonate salts, generating CO₂ to support rapid tablet disintegration.



Taste modification, softening bitter API profiles in paediatric and oral liquid dosage forms.



Process roles in lyophilisation, polymer crosslinking, and co-crystal / co-amorphous formulation strategies.




It is also pharmacopoeially well-established: monographs exist in the United States Pharmacopeia (USP) and the European Pharmacopoeia, and both the monohydrate and anhydrous forms are widely used.







Application 1: pH Control and Buffering in Liquid and Parenteral Drugs



This is the most common pharmaceutical use of citric acid. Most drug solutions — oral syrups, elixirs, injectables — require a controlled pH to keep the API stable, soluble, and bioavailable. A pH shift of even one unit can change an API's ionisation state, its solubility, and in some cases its degradation rate.



Citric acid forms buffer systems with its conjugate bases (monosodium, disodium, and trisodium citrate) that resist pH changes across a useful range for pharmaceutical formulations. This is why it appears in parenteral administration dosage forms, including intramuscular injections, as well as in oral solutions and topical preparations.



For injectable formulations, pharmacopoeial-grade citric acid (meeting USP or EP monograph requirements) is mandatory, and supply documentation must cover elemental impurities per ICH Q3D and nitrosamine risk assessment — a point that has become particularly sensitive since the regulatory tightening around nitrosamine contamination in drug products.







Application 2: Effervescent Tablets and Powders



The citric acid + sodium bicarbonate effervescent couple is one of the oldest and most effective solid dosage technologies. On contact with water, the acid and the carbonate react to release CO₂, which disintegrates the tablet, improves dissolution, and masks unpleasant API taste. Effervescent systems are standard for analgesics, antacids, effervescent multivitamins, and rehydration salts.



A more sophisticated application is gastro-retentive floating tablets: effervescent, buoyant tablets designed to float in gastric fluid and release their API slowly over hours. This technology is particularly useful for drugs with absorption windows limited to the upper gastrointestinal tract, or drugs unstable at intestinal pH. Literature describes this approach applied to verapamil, ciprofloxacin, dipyridamole, lisinopril, and venlafaxine, among others — covering antihypertensives, antibiotics, and antidepressants.



For these applications, the anhydrous form of citric acid is preferred: the monohydrate introduces water that can trigger premature reaction with the bicarbonate during manufacturing and storage, compromising tablet integrity and shelf life.







Application 3: Lyophilisation (Freeze-Drying) of Biologics and Labile APIs



Lyophilisation is a cornerstone process for stabilising biologics, peptides, and other heat-sensitive pharmaceuticals. Citric acid is a common excipient in lyophilised formulations, primarily for pH control both during the freezing stage and upon reconstitution.



The challenge in lyophilisation is that buffer components can crystallise at sub-zero temperatures, creating phase separations where local pH values diverge from the bulk formulation — potentially degrading sensitive actives. Citric acid's behaviour in this context has been extensively studied, including its glass transition behaviour. Anhydrous citric acid has a Tg of 11°C and the monohydrate a Tg of −25°C. These are properties of the pure excipient, not of the finished formulation: cycle design depends on Tg′, the glass transition of the maximally freeze-concentrated solution, which must be determined for the formulation as a whole. The excipient values inform that work rather than replace it. These values are critical when designing freeze-drying cycles and determining appropriate shelf temperatures.



A known formulation challenge: in solid state, citric acid retains its degree of ionisation and can cause sucrose protonation and inversion, which may then react with other formulation components and cause decomposition. Formulators designing lyophilised products with sucrose as cryoprotectant need to account for this interaction.







Application 4: Anticoagulant in Blood Collection and Apheresis



One of the most clinically important pharmaceutical uses of citric acid is not as an excipient but as the active component of anticoagulant solutions for extracorporeal blood processing. Anticoagulant Citrate Dextrose Solution USP (ACD Solution A), for example, contains 0.8% citric acid monohydrate, 2.2% sodium citrate dihydrate, and 2.45% dextrose monohydrate in water for injection, and is used in apheresis and platelet-rich plasma procedures.



The mechanism is straightforward but elegant: citrate acts as an extracorporeal anticoagulant by binding the free calcium in blood, and calcium is a necessary co-factor for several steps in the coagulation cascade. Remove the calcium, and the blood will not clot — but only where the citrate is present. Once the blood returns to the patient, citrate is rapidly metabolised and the anticoagulant effect disappears.



ACD first entered clinical use for apheresis in 1977 and is now preferred over heparin for centrifuge-based systems because it is cheaper, safer, and cleared from the body faster. It is a textbook example of a pharmaceutical where supply-chain quality and sterile-grade sourcing are non-negotiable: these solutions are sterilised by steam, packaged in polyolefin bags, and supplied under USP specification with full traceability.







Application 5: Solubility Enhancement, Co-Crystals, and Co-Amorphous Systems



A more recent area of pharmaceutical development concerns citric acid as a co-former in solid-state formulation strategies for poorly soluble APIs. Citric acid can form co-crystals and co-amorphous systems with APIs, improving their dissolution rate and bioavailability without chemically modifying the drug molecule itself.



Beyond solubility enhancement, citric acid is used in polymer excipients: for example, β-cyclodextrin polymers obtained by crosslinking β-cyclodextrin with citric acid have been developed as multifunctional direct-compression tablet excipients, offering compressibility and flowability suitable for tablet manufacturing.



These advanced applications reflect a broader trend: citric acid is no longer just a pH adjuster. In modern formulation science, it is increasingly exploited as a functional polymer building block and solid-state modifier.







Application 6: Taste Masking in Paediatric and Oral Liquid Formulations



Citric acid plays a discrete but important role in improving patient experience with oral liquid and chewable dosage forms. Bitter APIs — particularly many antibiotics and antivirals — are often unpalatable to the point that paediatric patients refuse them, compromising treatment compliance. Citric acid's tart flavour profile masks bitterness effectively, and the effect is enhanced when combined with sweeteners and flavouring agents.



In oral suspensions, solutions, and elixirs, citric acid's dual role as pH adjuster and taste modifier allows formulators to achieve both chemical stability and patient acceptability in a single ingredient — a particularly useful combination in paediatric formulation development.







Grades and Regulatory Requirements



For pharmaceutical use, only USP or EP pharmacopoeial-grade citric acid is acceptable. Key regulatory considerations include:




Compliance with the citric acid monograph in the relevant pharmacopoeia (USP, EP, JP).



Elemental impurities control per ICH Q3D.



Nitrosamine risk assessments, which have become a standard supplier expectation.



IPEC-GMP or pharmaceutical-grade GMP manufacturing standards for excipient supply.



Full traceability documentation: Certificate of Analysis (CoA), Safety Data Sheet (SDS), and in many cases a Drug Master File (DMF) reference to support regulatory submissions.



Choice between monohydrate and anhydrous forms, selected based on the process requirements (anhydrous for effervescent systems and dry blends; monohydrate for most liquid applications).




For a broader overview of excipient sourcing, documentation, and the role of specialty distributors in pharmaceutical supply chains, see our article on Active Pharmaceutical Ingredients and Excipients: The Distributor's Role.







Formulation Challenges to Watch



A few practical points that recur in pharmaceutical development:




Sucrose inversion in solid-state or lyophilised formulations — citric acid can protonate sucrose even in the solid state, producing invert sugar fragments that may react with other formulation components.



Moisture sensitivity in effervescent systems — the monohydrate form introduces enough water to trigger premature reaction with bicarbonate. Anhydrous is non-negotiable in these formulations.



Incompatibility with alkali-sensitive APIs — the acidic pH that citric acid establishes may destabilise APIs that require neutral or alkaline conditions.



Citrate toxicity in blood products — although this is a clinical rather than formulation concern, it is a documented reality of ACD-based apheresis: citrate reactions may occur with infusion and return of citrate-anticoagulated blood, with symptoms ranging from paraesthesia to hypotension.




Citric Acid Monohydrate vs Anhydrous — Frequently Asked Questions



What is the difference between citric acid monohydrate and anhydrous citric acid?



Both are the same molecule (C₆H₈O₇) but differ in water content. Anhydrous citric acid contains no water molecules in its crystalline structure, while the monohydrate form incorporates one water molecule per citric acid molecule (C₆H₈O₇·H₂O), giving it a molecular weight of 210.14 g/mol versus 192.12 g/mol for the anhydrous form and a water content of approximately 8.6%.



Which form is preferred for effervescent tablets and dry pharmaceutical formulations?



Anhydrous citric acid is the standard choice for effervescent tablets, dry blends, and solid dosage forms. The monohydrate formintroduces moisture that can trigger premature reaction with sodium bicarbonate during manufacturing or storage, compromising tabletintegrity and shelf life.



Is citric acid monohydrate suitable for liquid pharmaceutical formulations?



Yes. For oral syrups, liquid medications, and solutions, both forms are suitable — the water content of the monohydrate is not adrawback in aqueous systems. Monohydrate also tends to dissolve slightly faster initially, which can be an advantage in liquidprocessing. Final solubility in water is equivalent for both forms (approximately 59.2% at 20°C).



Which form is more stable during storage?



Monohydrate is generally more stable in humid environments. Anhydrous citric acid is hygroscopic — it actively absorbs moisture from theair — which makes controlled storage conditions essential when using the anhydrous form in solid formulations.



At what temperature does citric acid monohydrate convert to the anhydrous form?



36.6°C is the transition temperature in the aqueous system. Above it, the anhydrous form is the thermodynamically stable phase in solution, which matters for crystallisation and for any process with a heated aqueous stage.



It is not a solid-state dehydration threshold. Dry monohydrate does not lose its water of crystallisation simply by being stored at 40°C; solid-state dehydration requires substantially higher temperatures. Ordinary warm-climate storage therefore does not convert monohydrate to anhydrous, though the anhydrous form's hygroscopicity still makes humidity control the more important storage variable for solid formulations.



Citric acid earns its place in a pharmaceutical formulation by doing several jobs at once: holding pH, chelating trace metals, generating gas, masking bitterness. That versatility is also what makes it easy to specify carelessly. The form matters, the grade matters, and the interactions with sucrose, with bicarbonate and with alkali-sensitive actives all need to be designed for rather than discovered during stability testing.


USP and EP grade citric acid with CoA, DMF reference and full traceability documentation.

Pharmaceutical excipients

Citric Acid in Pharmaceutical Formulations: Functions, Applications, and Formulation Considerations

It looks like this molecule has broken down... but we’ll reconstitute it in no time.

The page you are looking for may have evaporated, been neutralized, or simply hasn’t been synthesized yet. We’ll help you find the right compound.

Formula not found!

Page not found title

Page not found

Twitter title

To view products available in a different region, please select your location below.

You are being redirected to the Safic-Alcan {country} catalog.

Safic Alcan - Home

You’ll be redirected to our main careers page to see the full details and apply.

View this job offer on our corporate website

To view the products available in your region, please select your location below.

Welcome to 
the Safic Alcan website!

About

Certifications & Documents

Countries covered

Markets covered

We couldn’t find any results matching your search. Explore our full range of specialty chemicals and solutions.

We couldn’t find any results matching your search.

No results found

Safic-Alcan, distributor of {supplier} {countryIn}. Explore the {supplier} product range and applications. Request a TDS, a sample or a quote.

Insights from the Industry